Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 74,360 Shares

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc purchased 74,360 shares of the company’s stock in a transaction on Wednesday, April 2nd. The stock was purchased at an average price of $11.85 per share, with a total value of $881,166.00. Following the completion of the transaction, the director now owns 17,382,566 shares of the company’s stock, valued at approximately $205,983,407.10. This trade represents a 0.43 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Monday, March 31st, Ecor1 Capital, Llc bought 4,397 shares of Zymeworks stock. The shares were purchased at an average price of $11.75 per share, for a total transaction of $51,664.75.
• On Wednesday, March 26th, Ecor1 Capital, Llc acquired 43,848 shares of Zymeworks stock. The stock was acquired at an average cost of $12.24 per share, with a total value of $536,699.52.
• On Monday, March 24th, Ecor1 Capital, Llc acquired 22,689 shares of Zymeworks stock. The shares were bought at an average cost of $13.08 per share, with a total value of $296,772.12.
• On Friday, March 21st, Ecor1 Capital, Llc bought 31,033 shares of Zymeworks stock. The shares were bought at an average cost of $12.78 per share, with a total value of $396,601.74.
• On Wednesday, March 19th, Ecor1 Capital, Llc acquired 58,306 shares of Zymeworks stock. The shares were purchased at an average price of $12.64 per share, with a total value of $736,987.84.
• On Monday, March 17th, Ecor1 Capital, Llc purchased 56,277 shares of Zymeworks stock. The shares were purchased at an average cost of $12.23 per share, with a total value of $688,267.71.
• On Thursday, March 13th, Ecor1 Capital, Llc bought 468,356 shares of Zymeworks stock. The stock was acquired at an average cost of $12.48 per share, with a total value of $5,845,082.88.
• On Tuesday, March 11th, Ecor1 Capital, Llc acquired 320,690 shares of Zymeworks stock. The shares were acquired at an average price of $11.49 per share, with a total value of $3,684,728.10.
• On Friday, January 17th, Ecor1 Capital, Llc purchased 19,748 shares of Zymeworks stock. The stock was acquired at an average cost of $13.87 per share, with a total value of $273,904.76.
• On Wednesday, January 15th, Ecor1 Capital, Llc acquired 39,029 shares of Zymeworks stock. The shares were bought at an average price of $14.01 per share, for a total transaction of $546,796.29.

Zymeworks Stock Performance

NYSE:ZYME traded up $0.30 during midday trading on Wednesday, reaching $11.92. 523,406 shares of the stock traded hands, compared to its average volume of 597,500. Zymeworks Inc. has a 12-month low of $7.97 and a 12-month high of $17.70. The business has a 50-day moving average of $13.50 and a two-hundred day moving average of $13.73. The stock has a market capitalization of $829.36 million, a PE ratio of -7.95 and a beta of 1.13.

Institutional Investors Weigh In On Zymeworks

Institutional investors have recently added to or reduced their stakes in the business. Sterling Capital Management LLC increased its stake in Zymeworks by 781.5% during the 4th quarter. Sterling Capital Management LLC now owns 1,719 shares of the company’s stock valued at $25,000 after purchasing an additional 1,524 shares in the last quarter. AlphaQuest LLC raised its stake in Zymeworks by 480.2% in the 4th quarter. AlphaQuest LLC now owns 2,808 shares of the company’s stock worth $41,000 after acquiring an additional 2,324 shares during the last quarter. FMR LLC lifted its position in Zymeworks by 84.2% during the 3rd quarter. FMR LLC now owns 3,336 shares of the company’s stock worth $42,000 after acquiring an additional 1,525 shares during the period. BNP Paribas Financial Markets purchased a new stake in Zymeworks during the 4th quarter valued at about $108,000. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Zymeworks by 343.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 9,704 shares of the company’s stock valued at $142,000 after purchasing an additional 7,518 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on ZYME shares. Lifesci Capital assumed coverage on shares of Zymeworks in a research note on Tuesday, March 11th. They set an “outperform” rating and a $30.00 price target for the company. Wells Fargo & Company upped their target price on Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a research note on Thursday, December 19th. JPMorgan Chase & Co. raised Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price target for the company in a research note on Monday, December 16th. HC Wainwright boosted their price objective on Zymeworks from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Monday, March 10th. Finally, Citigroup increased their target price on Zymeworks from $18.00 to $19.00 and gave the stock a “buy” rating in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.